PGEN Stock: Price, Earnings History and SEC Filings
Precigen, Inc. (PGEN) last traded at $6.94, up 4.52% on the latest session and down 18.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.05 against an analyst estimate of $-0.02, a beat of 350.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PGEN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $0.05 | $-0.02 | +350.00% |
| Mar 2026 | May 13, 2026 | $-0.02 | $-0.03 | +33.33% |
| Dec 2025 | Mar 25, 2026 | $-0.01 | $-0.10 | +90.00% |
| Sep 2025 | Nov 13, 2025 | $-0.11 | $-0.08 | -37.50% |
PGEN beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How PGEN reacts to earnings
Across its last 8 earnings releases, PGEN moved 10.2% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | After close | +5.51% |
| 2026-05-13 | After close | +10.84% |
| 2026-03-25 | After close | +25.48% |
| 2025-11-13 | After close | +25.65% |
| 2025-05-14 | After close | +2.34% |
| 2025-03-19 | After close | +0.56% |
| 2024-11-14 | After close | -6.82% |
| 2024-08-14 | After close | -4.46% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
PGEN financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $10M | -$251M | -$90M | -2588.2% | $-1.37 |
| 2024 | $4M | -$126M | -$77M | -3216.2% | $-0.47 |
| 2023 | $6M | -$96M | -$68M | -1540.6% | $-0.39 |
| 2022 | $27M | $28M | -$70M | 105.2% | $0.14 |
| 2021 | $14M | -$92M | -$63M | -646.0% | $-0.47 |
| 2020 | $32M | -$171M | -$85M | -533.0% | $-1.02 |
| 2019 | $91M | -$322M | -$174M | -355.3% | $-2.09 |
| 2018 | $151M | -$509M | -$166M | -336.9% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for PGEN
- 10-Q · Aug 4, 2026
- 8-K · Aug 4, 2026Results of operations
- 8-K · Jun 24, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 8-K · May 13, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 13, 2026
- DEF 14A · Apr 30, 2026
- 10-K · Mar 25, 2026
- 8-K · Mar 25, 2026Results of operations, Financial statements and exhibits
- 10-Q · Nov 13, 2025
- 8-K · Nov 13, 2025Results of operations, Financial statements and exhibits
Insider filing activity
PGEN insiders filed 9 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
PGEN news
- PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA ApprovalOct 30, 2026 · stocktwits.com
- C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 29, 2026 · finance.yahoo.com
- Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4Oct 28, 2026 · finance.yahoo.com
- Precigen (PGEN) Stock May Be Fully Priced On Its Huge 3 Year RunOct 20, 2026 · finance.yahoo.com
About Precigen, Inc.
Precigen, Inc. (PGEN) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in VA. Its fiscal year ends in December.